The prospects that Johnson & Johnson will reach a new agreement to buy Guidant appeared to diminish yesterday, with people involved in the talks expressing for the first time skepticism that the companies will be able to resuscitate the transaction.
The companies remained at an impasse over the price of a renegotiated deal, the people involved said, with each side expressing increased frustration with the other. The initial deal was worth $25.4 billion, or $76 a share.
